Brought to you by 
Foundation Medicine licenses FoundationOne assay to WuXi
12 Feb 2015
Executive Summary
Foundation Medicine Inc. (FMI) licensed WuXi PharmaTech Inc. rights to use the lab component of its FoundationOne tumor profiling product in China.
Deal Industry
- In Vitro Diagnostics
- Services
-
In Vitro Diagnostics
- Molecular Diagnostics & Genetic Testing
-
Biotechnology
- Pharmacogenetics-Pharmacogenomics
Deal Status
- Final
Deal Type
-
Alliance
- Intra-Biotech Deal
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Foundation Medicine licenses FoundationOne assay to WuXi
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice